Hot Features
프리미엄
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
VANCOUVER, British Columbia, Feb. 26, 2015 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") is a biotechnology company dedicated to the development and...
VANCOUVER, British Columbia, Jan. 5, 2015 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced that Mr. Glen Ibbott has been appointed as the Interim...
VANCOUVER, British Columbia, Dec. 16, 2014 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") is pleased to announce that, on a vote by ballot, the six incumbent...
VANCOUVER, British Columbia, July 14, 2014 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced the publication of data from its Phase 1b proof-of-concept...
VANCOUVER, British Columbia, April 30, 2014 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") is a biotechnology company dedicated to the development and...
VANCOUVER, British Columbia, Feb. 28, 2014 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") is a biotechnology company dedicated to the development and...
VANCOUVER, British Columbia, Feb. 27, 2014 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced positive preliminary results from its international...
VANCOUVER, British Columbia, Dec. 9, 2013 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced that the first patient has been dosed in the Company's...
Plans for Phase IIa Proof-of-Concept Trial for QLT091001 in Impaired Dark Adaptation Company to Provide Guidance on Pivotal Studies in Orphan Indications Before the End of Q1...
VANCOUVER, British Columbia, Nov. 11, 2013 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced that Vicente Anido, Jr. has resigned from the Board of...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
